Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors

Launched by INDIANA UNIVERSITY · Nov 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the long-term heart health of men who have survived testicular cancer, particularly those who received certain types of chemotherapy and may have undergone a bone marrow transplant. Researchers want to understand if these treatments have any lasting effects on the heart, even if patients are currently cancer-free. The trial is looking for men aged 18 and older who have been diagnosed with testicular cancer and meet specific criteria based on their treatment history.

To participate, men must be cancer-free at the time of evaluation and have either received chemotherapy or had surgery for their testicular cancer. Those with a history of heart disease or certain other health issues, like significant kidney problems, cannot join the study. If eligible, participants can expect to undergo evaluations to assess their heart health and help researchers learn more about the potential risks of heart disease in testicular cancer survivors. This important research aims to improve care and support for those who have battled cancer.

Gender

MALE

Eligibility criteria

• • Inclusion Criteria
• • Patients \>18 years of age
• • Patients will be recruited only if cancer-free at clinical evaluation time.
• • For the cases a confirmed TC diagnosis who received one or more cycles of CBCT-based chemotherapies (CBCT group, Arm 2)
• • For the cases with a confirmed TC diagnosis who received one or more cycles of CBCT-based chemotherapies and underwent BMT for relapsed refractory disease (CBCT \& BMT group, Arm 3).
• • For the comparison cohort, biopsy-proven TC patients who had surgery for or surveillance of their testicular cancer and never received CBCTCBCT or BMT (surgical/surveillance, Arm 1)
• • Exclusion Criteria
• • Prior known myocardial infarction (MI), atherosclerotic cardiovascular disease (ASCVD)
• • Significant renal disease (GFR\<40)
• • Allergy to iodinated contrast
• • Antecedent chemotherapy for another primary cancer.